The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry

The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

REPORT HIGHLIGHTS AND KEY FINDINGS

• The current market for drugs to treat sexual disorders is estimated at US$3.8 billion, which is forecast to increase 74% to US$6.6 billion by 2012
• Critical analysis of marketed sexual dysfunction drugs related to erectile dysfunction and androgen deficiency
• Analysis of over 20 key marketed and pipeline products and inclusion of 43 R&D candidates identified in preclinical to clinical stages of development
• Sales estimates (US$) to 2012 for leading products
• Strategic insights for life-cycle optimization and product development
• Commercial evaluation of leading sexual disorder pharmacotherapies
• Trend analysis of industry events and activities over past 2 years
• Detailed R&D themes and clusters by therapy area
• Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)
• High revenue-yielding prospects identified with projected sales estimations
• R&D pipeline positioning for novel candidates
• Market insights for product development and drug promotion

WHAT CAN I LEARN FROM THIS REPORT?

• Which drugs are the current and potential future market leaders in the sexual dysfunction therapy domain
• Insights into utility of androgenic drugs to treat male andropause and female sexual disorders
• What impact new drug approvals will have on the sexual medicine drug market
• Which premarket drugs are identified as high-value products
• Which companies are developing drugs for male and female sexual disorders
• Sales predictions to 2012 for male sexual dysfunction therapies
• How will newcomers affect the product positioning of market leaders
• What are the niche market opportunities in sexual dysfunction
• What the future outlook may hold for sexual disorder pharmacotherapies
How companies are expanding the global sexual medicine market through new indications and therapeutic switching
• Which molecules and compounds are main R&D clusters in sexual dysfunction drug development
• Which of the pipeline candidates are identified as top prospects over the next decade and to 2020